SK Bioscience Confirms IPO Price at 65,000 Won
Institutional Investor Demand Forecast at 1275.47 to 1
General Investor Subscription Scheduled for March 9-10
[Asia Economy Reporter Han Jinju] SK Bioscience has set its public offering price at 65,000 KRW.
On the 8th, SK Bioscience announced that it finalized the public offering price at the upper end of the desired range, 65,000 KRW, following the demand forecast for institutional investors conducted over two days starting from the 4th.
Accordingly, the total public offering amount was decided to be approximately 1.4918 trillion KRW. A total of 1,464 institutions participated in the demand forecast for institutional investors, recording a competition rate of 1,275.47 to 1.
General investor subscriptions for SK Bioscience will be accepted from the 9th to the 10th at six securities firms: NH Investment & Securities, Korea Investment & Securities, Mirae Asset Daewoo, SK Securities, Samsung Securities, and Hana Financial Investment.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- How Investment Strategies Differ Between 70s and 20s Retail Investors
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
SK Bioscience will be listed on the KOSPI market on the 18th. SK Bioscience is responsible for developing and contract manufacturing COVID-19 vaccines. Its self-developed vaccine candidates have entered clinical trials, and it has signed production contracts for vaccine candidates with global companies such as AstraZeneca and Novavax.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
